Red Flags Detected

• ⚠ Going Concern (new) — Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
• ⚠ Material Weakness (new) — The company has an unremediated material weakness in internal control over financial reporting as of December 31, 2024, which remains unremediated as of September 30, 2025.
• ⚠ Single Employee (new) — The company has only one full-time employee, its CEO, which is a significant operational risk.
• ⚠ No Approved Products (new) — The company has no products approved for sale and cannot guarantee it will ever have marketable drugs.
• ⚠ Focus On Cd47 Immune Checkpoint Inhibitor (new) — The company's limited resources are concentrated on a single product candidate, the CD47 immune checkpoint inhibitor.
• ⚠ Early-stage Pipeline (new) — All internal programs are preclinical or research-stage, meaning no product candidate has entered clinical trials.
• ⚠ Termination of Car-t and Vaccine Licenses (new) — The company's core CAR-T and vaccine product licenses were terminated by TDT in August 2024.
• ⚠ Related-party Debt Conversions (new) — Multiple related-party loans were converted into common stock upon the business combination, reducing debt but diluting existing shareholders.
• ⚠ Short-term Debt Balance (new) — All outstanding debt agreements are past due, though the company states they are not in default due to mutual deferral agreements with related parties.